:’
In a significant move to bolster its financial resources and advance its pioneering treatments, INmune Bio Inc. (Nasdaq: INMB) has successfully closed a $13.0 million registered direct offering. This capital influx is set to fortify the company’s ongoing work in tackling inflammation and immunology through the enhancement of patients’ innate immune systems.
INmune Bio Inc. a clinical-stage company centered around inflammation and immunology, has revealed a successful closure of a $13.0 million registered direct offering. By entering into securities purchase agreements with both new and existing institutional investors, as well as insiders of the company, INmune Bio aims to escalate its development of innovative immunotherapy treatments.
Capital Raise Details:’
The offering saw the sale of 2,341,260 shares of INmune Bio’s common stock, accompanied by warrants to purchase an equivalent number of shares. Institutional investors acquired their shares at a combined purchase price of $5.50 per share and accompanying warrant, whereas Officers and Directors, along with other employees of the company, participated at a price of $6.50 per share and accompanying warrant. These warrants are exercisable starting six months from the issue date, priced at $6.40 per share, and hold a lifespan extending five years from the initial exercise date.
It is noteworthy that the warrant term incorporates conditions that could accelerate the termination date. For insiders, if this termination occurs during a blackout period, they will receive an extension of 60 days following the blackout period to exercise their warrants.
Implications for Research and Development:’
This infusion of capital is poised to significantly enhance INmune Bio’s capabilities in its core research areas. The company’s innovative approach leverages the patient’s innate immune system as a defense mechanism against various diseases. With these financial resources, INmune Bio is well-positioned to further its development pipeline, potentially accelerating the availability of new immunotherapy treatments to patients in need.
Conclusion:’
INmune Bio’s recent $13.0 million direct offering is a monumental stride in the company’s journey towards pioneering therapies in the domain of inflammation and immunology. This strategic funding, backed by committed institutional investors and steadfast confidence from its insiders, underpins the company’s mission to advance the field of innate immunotherapy.
Comments